Guardant Health, Inc. - Common Stock (NQ:GH)

177.80 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

22 23 Next >

New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap

March 01, 2024

From Guardant Health, Inc.

Via Business Wire

Cancer Test Focused Guardant Health Stock Falls On FDA AdCom Update For Colorectal Test ↗

February 23, 2024

Guardant Health surpasses Q4 2023 revenue expectations, reporting $155.1 million. Precision oncology revenue is up 25% to $142.2 million. Adjusted EPS loss beats consensus. Update on Shield CRC...

Via Benzinga

4 Analysts Have This To Say About Guardant Health ↗

February 23, 2024

Via Benzinga

Guardant Health: Q4 Earnings Insights ↗

February 22, 2024

Via Benzinga

Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

February 22, 2024

From Guardant Health, Inc.

Via Business Wire

Decoding 4 Analyst Evaluations For Guardant Health ↗

January 30, 2024

Via Benzinga

What 7 Analyst Ratings Have To Say About Guardant Health ↗

December 13, 2023

Via Benzinga

7 Analysts Have This to Say About Guardant Health ↗

November 13, 2023

Via Benzinga

Guardant Health to Participate in Upcoming Investor Conferences

February 15, 2024

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

February 01, 2024

From Guardant Health, Inc.

Via Business Wire

3 Stocks to Buy for the Age of Personalized Medicine ↗

January 28, 2024

Personalized medicine stocks can unlock significant growth from your portfolio. Here are three companies to consider.

Via InvestorPlace

Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence

January 17, 2024

From Guardant Health, Inc.

Via Business Wire

Bull of the Day - NeoGenomics ↗

January 12, 2024

But in late December, shares took a big hit on patent litigation with competitor Natera. Let's review the primary commercial business of NEO and then that will help put the legal news into context.

Via Talk Markets

Topics Intellectual Property

7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024 ↗

January 08, 2024

Small cap stocks are anticipated to rise by as much as 50% in 2024 as investors look for growth in new areas of the market.

Via InvestorPlace

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results

January 08, 2024

From Guardant Health, Inc.

Via Business Wire

4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 ↗

January 08, 2024

Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run.

Via The Motley Fool

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

January 08, 2024

From Guardant Health, Inc.

Via Business Wire

Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer

January 02, 2024

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford

December 21, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 20, 2023

From Guardant Health, Inc.

Via Business Wire

Blood-Based Colorectal Cancer CRC Screening Market Likely to Benefit From FDA's Panel Surprise Advisory Possibility: Analyst ↗

December 20, 2023

Tuesday, Guardant Health Inc (NASDAQ: GH) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket...

Via Benzinga

S&P 500, Nasdaq Set For Weaker Open As 'FOMO' Rally Cools: Analyst Says Only 'Black Swan Could Upset Santa's Sleigh' Now ↗

December 20, 2023

Bond yields remain contained, providing a reason for traders to maintain their investments in stocks.

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

December 19, 2023

Via Benzinga

Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test

December 19, 2023

From Guardant Health, Inc.

Via Business Wire

Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities

December 04, 2023

From Guardant Health, Inc.

Via Business Wire

Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection

November 30, 2023

From Guardant Health, Inc.

Via Business Wire

Jim Cramer: Buy This Financial Stock, 'It's Up Substantially From Where It Was In The Spring' ↗

November 28, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he remains a buyer of SoFi Technologies, Inc. (NASDAQ: SOFI).

Via Benzinga

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 15, 2023

From Guardant Health, Inc.

Via Business Wire

Why Is Cancer Blood Test-Focused Guardant Health Stock Trading Lower Today? ↗

November 15, 2023

Guardant Health Inc (NASDAQ: GH) shares are falling after the company announced it intends to appeal its verdict in the U.S.

Via Benzinga

Guardant Health to Appeal Federal District Court Verdict

November 15, 2023

From Guardant Health, Inc.

Via Business Wire

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.